Nabil Hanna, PhD
President, Invision Biotherapy

Dr. Hanna is former Executive Vice President of Research at Biogen Idec. He assumed this responsibility after the merger of IDEC Pharmaceutical and Biogen in 2002. From 1990 to 2002, Dr. Hanna served as VP of Research then was promoted to Sr.VP of Research and Pre-Clinical Development and then Chief Scientific Officer at IDEC Pharmaceuticals. During his tenure at IDEC, Dr. Hanna led a research team through the discovery and pre-clinical development of Rituximab and Zevalin, two antibodies now approved for therapy of non-Hodgkin’s B cell lymphoma. From 1981 to 1990, Dr. Hanna served as a Director of the Department of Immunology at SmithKline Beecham focusing on autoimmune and chronic inflammatory diseases. From 1978 to 1981, he was a research scientist at the NCI-Frederick Cancer Research Center, where he studied the role of natural host defenses against cancer metastasis. From 1973 to 1978, Dr. Hanna was a lecturer in the Department of Immunology at Hebrew University Medical Center in Israel, where he received his Ph.D. in Immunology.

Mark Pegram, MD
Professor of Medicine, Division of Hematology and Oncology, UCLA School of Medicine

Dr. Mark Pegram is Professor of Medicine in the Division of Hematology/Oncology at the UCLA School of Medicine, and is currently Director of the Women’s Cancer Program at the UCLA/Jonsson Comprehensive Cancer Center. Dr. Pegram took his medical training at the University of North Carolina, Chapel Hill and attended medical internship and residency at the University of Texas Southwestern Medical School in Dallas, TX (Parkland Memorial Hospital) before moving to UCLA for fellowship training in Hematology/Oncology. Dr. Pegram conducted his research fellowship in Dr. Dennis Slamon’s laboratory at UCLA before joining the UCLA faculty in 1993. Dr. Pegram has a number of honors and awards to his credit including the Revlon/UCLA Fellowship, the UCLA Clinical Cancer Research Career Development Award, and the Basic Science Award from the Society of Gynecologic Oncology. Dr. Pegram’s expertise is in the development of targeted therapeutics in solid tumor oncology. Dr. Pegram has grant support for his work in the area of targeting growth factor receptors and angiogenesis in breast cancer. Dr. Pegram has numerous publications to his credit including authorships or co-authorships in the New England Journal of Medicine, Journal or the National Cancer Institute, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Biochemistry, Oncogene, Journal of Organic Chemistry, Clinical Cancer Research, Biochemical Pharmacology, Cancer Gene Therapy, and Breast Cancer Research and Treatment.